发布求助
文献互助 智能选刊 最新文献

Trends in cancer最新文献

筛选
英文 中文
A new enhancer for anti-PD-1/PD-L1 immunotherapy: PCSK9 inhibition. 抗 PD-1/PD-L1 免疫疗法的新增强剂：PCSK9 抑制剂
IF 14.3 1区 医学
Trends in cancer Pub Date : 2025-02-01 Epub Date: 2024-10-24 DOI: 10.1016/j.trecan.2024.10.002
Shengbo Sun, Zhengyang Yang, Hongwei Yao, Zhongtao Zhang
{"title":"A new enhancer for anti-PD-1/PD-L1 immunotherapy: PCSK9 inhibition.","authors":"Shengbo Sun, Zhengyang Yang, Hongwei Yao, Zhongtao Zhang","doi":"10.1016/j.trecan.2024.10.002","DOIUrl":"10.1016/j.trecan.2024.10.002","url":null,"abstract":"<p><p>Anti-programmed cell death protein 1 (PD-1)/PD-1 ligand 1 (PD-L1) immunotherapy has shown promising results in cancer treatment, improving clinical outcomes and prolonging patient survival. However, most patients exhibit low response rates to PD-1/PD-L1 blockade, highlighting the urgent need for new enhancers. Increasing data now demonstrate that inhibiting proprotein convertase subtilisin/kexin type 9 (PCSK9), a serine proteinase, can enhance the antitumor efficacy of anti-PD-1/PD-L1 immunotherapy.</p>","PeriodicalId":23336,"journal":{"name":"Trends in cancer","volume":" ","pages":"84-87"},"PeriodicalIF":14.3,"publicationDate":"2025-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142508856","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Transcriptional regulation of hypoxic cancer cell metabolism and artificial intelligence. 缺氧癌细胞新陈代谢的转录调控与人工智能。
IF 14.3 1区 医学
Trends in cancer Pub Date : 2025-02-01 Epub Date: 2024-10-30 DOI: 10.1016/j.trecan.2024.10.003
Luana Schito, Sergio Rey-Keim
{"title":"Transcriptional regulation of hypoxic cancer cell metabolism and artificial intelligence.","authors":"Luana Schito, Sergio Rey-Keim","doi":"10.1016/j.trecan.2024.10.003","DOIUrl":"10.1016/j.trecan.2024.10.003","url":null,"abstract":"<p><p>Gene expression regulation in hypoxic tumor microenvironments is mediated by O<sub>2</sub> responsive transcription factors (O<sub>2</sub>R-TFs), fine-tuning cancer cell metabolic demand for O<sub>2</sub> according to its availability. Here, we discuss key O<sub>2</sub>R-TFs and emerging artificial intelligence (AI)-based applications suitable for the interrogation of O<sub>2</sub>R-TF relationships specifying cancer cell metabolic adaptations to hypoxia.</p>","PeriodicalId":23336,"journal":{"name":"Trends in cancer","volume":" ","pages":"88-90"},"PeriodicalIF":14.3,"publicationDate":"2025-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142558877","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
KRAS inhibitors: resistance drivers and combinatorial strategies. KRAS抑制剂：耐药驱动和组合策略。
IF 14.3 1区 医学
Trends in cancer Pub Date : 2025-02-01 Epub Date: 2024-12-27 DOI: 10.1016/j.trecan.2024.11.009
Tamara Isermann, Christine Sers, Channing J Der, Bjoern Papke
{"title":"KRAS inhibitors: resistance drivers and combinatorial strategies.","authors":"Tamara Isermann, Christine Sers, Channing J Der, Bjoern Papke","doi":"10.1016/j.trecan.2024.11.009","DOIUrl":"10.1016/j.trecan.2024.11.009","url":null,"abstract":"<p><p>In 1982, the RAS genes HRAS and KRAS were discovered as the first human cancer genes, with KRAS later identified as one of the most frequently mutated oncogenes. Yet, it took nearly 40 years to develop clinically effective inhibitors for RAS-mutant cancers. The discovery in 2013 by Shokat and colleagues of a druggable pocket in KRAS paved the way to FDA approval of the first covalently binding KRAS<sup>G12C</sup> inhibitors, sotorasib and adagrasib, in 2021 and 2022, respectively. However, rather than marking the end of a successful assault on the Mount Everest of cancer research, this landmark only revealed new challenges in RAS drug discovery. In this review, we highlight the progress on defining resistance mechanisms and developing combination treatment strategies to improve patient responses to KRAS therapies.</p>","PeriodicalId":23336,"journal":{"name":"Trends in cancer","volume":" ","pages":"91-116"},"PeriodicalIF":14.3,"publicationDate":"2025-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142898407","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Short-chain fatty acids and cancer. 短链脂肪酸和癌症。
IF 14.3 1区 医学
Trends in cancer Pub Date : 2025-02-01 Epub Date: 2024-12-04 DOI: 10.1016/j.trecan.2024.11.003
Shan Li, Yixin Duan, Shudi Luo, Fangxin Zhou, Qingang Wu, Zhimin Lu
{"title":"Short-chain fatty acids and cancer.","authors":"Shan Li, Yixin Duan, Shudi Luo, Fangxin Zhou, Qingang Wu, Zhimin Lu","doi":"10.1016/j.trecan.2024.11.003","DOIUrl":"10.1016/j.trecan.2024.11.003","url":null,"abstract":"<p><p>Short-chain fatty acids (SCFAs), derived from the diet and the microbiota, serve as crucial links between the diet, gut microbiota, metabolism, immunity, and cancer. They function as energy sources through β-oxidation and regulate macromolecular synthesis, G protein-coupled receptor (GPCR) and histone deacetylase (HDAC) activities, protein modifications, signaling pathways, and gene expression in cells within the tumor microenvironment, particularly in tumor and immune cells. The critical role of SCFAs in maintaining normal homeostasis and influencing tumor progression highlights the potential of targeting SCFA-mediated cellular processes for cancer prevention and treatment.</p>","PeriodicalId":23336,"journal":{"name":"Trends in cancer","volume":" ","pages":"154-168"},"PeriodicalIF":14.3,"publicationDate":"2025-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142787133","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Revumenib: a new era in acute leukemia treatment.
IF 14.3 1区 医学
Trends in cancer Pub Date : 2025-02-01 Epub Date: 2025-01-24 DOI: 10.1016/j.trecan.2025.01.006
David A Martínez-Gamboa, Justin Kaner
{"title":"Revumenib: a new era in acute leukemia treatment.","authors":"David A Martínez-Gamboa, Justin Kaner","doi":"10.1016/j.trecan.2025.01.006","DOIUrl":"10.1016/j.trecan.2025.01.006","url":null,"abstract":"<p><p>The AUGMENT-101 clinical trial reported that the use of revumenib led to improved overall survival (OS) and complete remission (CR)/CR with partial hematologic recovery (CRh) in patients with acute leukemias and has released updated data with longer follow-up of Phase 2 results. Additionally, revumenib has received FDA approval for its use in relapsed or refractory (r/r) lysine methyltransferase 2A rearranged (KMT2A-r) acute leukemias.</p>","PeriodicalId":23336,"journal":{"name":"Trends in cancer","volume":" ","pages":"81-83"},"PeriodicalIF":14.3,"publicationDate":"2025-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143042373","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Think zebras: challenges and opportunities for treating rare cancers.
IF 14.3 1区 医学
Trends in cancer Pub Date : 2025-02-01 Epub Date: 2025-01-28 DOI: 10.1016/j.trecan.2025.01.004
Sam Behjati, Jesse S Boehm, Matthew D Dun, Stefan Fröhling, Paul H Huang, Nada Jabado, Ning Li, Carla Daniela Robles-Espinoza
{"title":"Think zebras: challenges and opportunities for treating rare cancers.","authors":"Sam Behjati, Jesse S Boehm, Matthew D Dun, Stefan Fröhling, Paul H Huang, Nada Jabado, Ning Li, Carla Daniela Robles-Espinoza","doi":"10.1016/j.trecan.2025.01.004","DOIUrl":"10.1016/j.trecan.2025.01.004","url":null,"abstract":"","PeriodicalId":23336,"journal":{"name":"Trends in cancer","volume":" ","pages":"75-80"},"PeriodicalIF":14.3,"publicationDate":"2025-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143060832","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Evolution of first versus next-line targeted therapies for metastatic non-small cell lung cancer.
IF 14.3 1区 医学
Trends in cancer Pub Date : 2025-01-30 DOI: 10.1016/j.trecan.2025.01.005
Sarah Waliany, Jessica J Lin, Justin F Gainor
{"title":"Evolution of first versus next-line targeted therapies for metastatic non-small cell lung cancer.","authors":"Sarah Waliany, Jessica J Lin, Justin F Gainor","doi":"10.1016/j.trecan.2025.01.005","DOIUrl":"https://doi.org/10.1016/j.trecan.2025.01.005","url":null,"abstract":"<p><p>The expanding armamentarium of targeted therapies has revolutionized treatment for metastatic oncogene-addicted lung cancers. For multiple subsets, such as those harboring EGFR mutations and fusions in ALK or ROS1, successive generation of increasingly potent, selective, and brain-penetrating targeted therapies have shifted the treatment paradigm towards preferential first-line use of next-generation drugs. This evolution in clinical practice provides a lens through which to review the lessons learned from drug development in oncogene-addicted lung cancers, guided by translational insights into tumor biology and mechanisms of therapeutic resistance. For oncogenic drivers that are less sensitive to single-agent targeted therapies, rationally designed combination strategies will be needed to enable first-line use of targeted agents.</p>","PeriodicalId":23336,"journal":{"name":"Trends in cancer","volume":" ","pages":""},"PeriodicalIF":14.3,"publicationDate":"2025-01-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143075650","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Sensory neurotransmission and pain in solid tumor progression.
IF 14.3 1区 医学
Trends in cancer Pub Date : 2025-01-29 DOI: 10.1016/j.trecan.2025.01.003
Andre A Martel Matos, Nicole N Scheff
{"title":"Sensory neurotransmission and pain in solid tumor progression.","authors":"Andre A Martel Matos, Nicole N Scheff","doi":"10.1016/j.trecan.2025.01.003","DOIUrl":"https://doi.org/10.1016/j.trecan.2025.01.003","url":null,"abstract":"<p><p>Sensory nerves form a crucial component of the tumor microenvironment (TME) that relays vital information to the central nervous system and modulates tumor progression via immunosurveillance. Afferent activity processed by the brain can sensitize brain circuitry and influence host behaviors. Peripheral sensory signaling (e.g., release of neuropeptides in the TME) can drive phenotypic changes in the tumor immune response, such as increased exhaustion markers and inhibited effector cell activity, which promote cancer progression. In this review we highlight the most recent evidence demonstrating the pivotal role of the sensory nervous system in cancer, with a focus on primary tumor pain, and we discuss the extent to which pain can influence cancer progression and treatment response, including immunotherapeutic strategies.</p>","PeriodicalId":23336,"journal":{"name":"Trends in cancer","volume":" ","pages":""},"PeriodicalIF":14.3,"publicationDate":"2025-01-29","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143068113","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Oncogenic competence: balancing mutations, cellular state, and microenvironment.
IF 14.3 1区 医学
Trends in cancer Pub Date : 2025-01-28 DOI: 10.1016/j.trecan.2025.01.002
Lisa Pavinato, Arianna Baggiolini
{"title":"Oncogenic competence: balancing mutations, cellular state, and microenvironment.","authors":"Lisa Pavinato, Arianna Baggiolini","doi":"10.1016/j.trecan.2025.01.002","DOIUrl":"https://doi.org/10.1016/j.trecan.2025.01.002","url":null,"abstract":"<p><p>Cancer development is driven by mutations, yet tumor-causing mutations only lead to tumor formation within specific cellular contexts. The reasons why certain mutations trigger malignant transformation in some contexts but not others remain often unclear. Both intrinsic and extrinsic factors play a key role in driving carcinogenesis by leading the cells toward a state of 'oncogenic competence'. This state is shaped by the transcriptional and epigenetic programs that define a specific cell in time and space. These programs arise from the interplay between genetic mutations, cellular lineage, differentiation state, and microenvironment. A deeper understanding of oncogenic competence is essential to uncover the mechanisms behind tumor initiation and, ultimately, advance the development of novel targeted therapies for cancer treatment and prevention.</p>","PeriodicalId":23336,"journal":{"name":"Trends in cancer","volume":" ","pages":""},"PeriodicalIF":14.3,"publicationDate":"2025-01-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143060830","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Cancer evolution: from Darwin to the Extended Evolutionary Synthesis.
IF 14.3 1区 医学
Trends in cancer Pub Date : 2025-01-28 DOI: 10.1016/j.trecan.2025.01.001
Thomas Savy, Lucy Flanders, Thaneswari Karpanasamy, Min Sun, Marco Gerlinger
{"title":"Cancer evolution: from Darwin to the Extended Evolutionary Synthesis.","authors":"Thomas Savy, Lucy Flanders, Thaneswari Karpanasamy, Min Sun, Marco Gerlinger","doi":"10.1016/j.trecan.2025.01.001","DOIUrl":"https://doi.org/10.1016/j.trecan.2025.01.001","url":null,"abstract":"<p><p>The fundamental evolutionary nature of cancer has been recognized for decades. Increasingly powerful genetic and single cell sequencing technologies, as well as preclinical models, continue to unravel the evolution of premalignant cells, and progression to metastatic stages and to drug-resistant end-stage disease. Here, we summarize recent advances and distil evolutionary principles and their relevance for the clinic. We reveal how cancer cell and microenvironmental plasticity are intertwined with Darwinian evolution and demonstrate the need for a conceptual framework that integrates these processes. This warrants the adoption of the recently developed Extended Evolutionary Synthesis (EES).</p>","PeriodicalId":23336,"journal":{"name":"Trends in cancer","volume":" ","pages":""},"PeriodicalIF":14.3,"publicationDate":"2025-01-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143068108","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
首页 上一页 下一页 尾页
0
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整，为了账户安全，请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
请完成安全验证×
相关产品
×
本文献相关产品
联系我们：info@booksci.cn Book学术提供免费学术资源搜索服务，方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号：481959085
Book学术官方微信